Residency · Residency · Nuclear Medicine

Tc-99m: Generator System and Kit Preparation

The Mo-99/Tc-99m Generator

Production of Mo-99

Mo-99, the parent radionuclide in the Tc-99m generator, is produced primarily through uranium-235 fission in nuclear reactors. When U-235 absorbs a neutron and undergoes fission, Mo-99 is among the resulting fission products, with a fission yield of approximately 6.1%. Most current production facilities use highly enriched uranium (HEU) targets, though a global transition to low-enriched uranium (LEU) targets is underway for nuclear non-proliferation reasons. Historically, the major production reactors have included the NRU in Canada (decommissioned in 2018), the HFR in the Netherlands, BR2 in Belgium, SAFARI-1 in South Africa, and OPAL in Australia. A critical vulnerability of the Mo-99 supply chain is that only a handful of aging reactors produce the world's supply, leading to multiple supply crises, with the most severe occurring in 2009-2010. Alternative production methods are under development, including cyclotron-produced Tc-99m via the Mo-100(p,2n)Tc-99m reaction, neutron capture using the Mo-98(n,gamma)Mo-99 pathway (which yields lower specific activity), and linear accelerator-based Mo-99 production.

Generator Principle

The generator exploits the parent-daughter relationship between Mo-99 (half-life 66 hours) and Tc-99m (half-life 6 hours). Mo-99 decays to Tc-99m by beta-minus emission, establishing a transient equilibrium in which the parent half-life is longer than the daughter half-life but not more than tenfold longer. In the generator, Mo-99 in the form of molybdate (MoO4^2-) is adsorbed onto an alumina (Al2O3) column. Because Tc-99m pertechnetate (TcO4-) has different chemical properties from molybdate, it can be selectively washed off the column with normal saline while the molybdate remains bound.

Elution Process

To obtain Tc-99m, sterile normal saline (0.9% NaCl) is drawn through the alumina column, and the Tc-99m pertechnetate elutes into a sterile, evacuated collection vial. A typical elution volume ranges from 5 to 20 mL. Maximum Tc-99m activity is available approximately 23 hours after the previous elution, when transient equilibrium has been reestablished. The generator can be eluted multiple times per day, but yield decreases with shorter intervals between elutions because insufficient Tc-99m has had time to accumulate. A generator remains usable for approximately 1 to 2 weeks before the Mo-99 activity decays to impractically low levels.

Transient Equilibrium

After an elution strips the column of Tc-99m, the daughter begins to build up again as Mo-99 continues to decay. The daughter activity reaches a maximum at a time given by the formula t_max = [1.44 x T_p x T_d / (T_p - T_d)] x ln(T_p/T_d), which for the Mo-99/Tc-99m system works out to approximately 23 hours. At equilibrium, the Tc-99m activity slightly exceeds the Mo-99 activity by a factor of T_p / (T_p - T_d), approximately 1.1. This situation contrasts with secular equilibrium, which occurs when the parent half-life is more than tenfold longer than the daughter half-life (as in the Ge-68/Ga-68 generator). In secular equilibrium, the daughter activity equals the parent activity at equilibrium.

Generator Quality Control

Mo-99 Breakthrough

Small amounts of Mo-99 may elute along with the Tc-99m, a phenomenon called Mo-99 breakthrough. The NRC limit is no more than 0.15 microCi of Mo-99 per mCi of Tc-99m at the time of administration. To test for breakthrough, the eluate is placed inside a lead pig with 6 mm lead walls. The lead absorbs the 140 keV Tc-99m gamma rays but transmits the higher-energy 740/780 keV Mo-99 gammas. Activity is measured in a dose calibrator both with and without the lead pig to determine the Mo-99 contribution. Breakthrough is more likely with older generators or aggressive elution schedules. Excess Mo-99 in the administered dose is a concern because it is a beta emitter with a 66-hour half-life, delivering unnecessary radiation dose to the patient.

Al-27 Breakthrough

Aluminum ions from the alumina column may also elute with the pertechnetate. The USP limit is no more than 10 micrograms of aluminum per mL of eluate. Testing uses a colorimetric spot test with aurintricarboxylic acid indicator: the color intensity of a spot of eluate is compared against a standard reference. Excess aluminum is problematic because it causes aggregation of certain radiopharmaceuticals (especially sulfur colloid) and can alter biodistribution.

Other QC Tests

Additional quality control measures include visual inspection (the eluate should be clear, colorless, and free of particulates), pH testing (acceptable range 4.5 to 7.5), radionuclidic purity verification by half-life determination (should approximate 6 hours), volume measurement, and sterility and endotoxin testing (performed by the manufacturer with spot checks per institutional policy).

Tc-99m Pertechnetate Chemistry

Oxidation States

Technetium can exist in multiple oxidation states, ranging from +7 down to +1. In its eluted form, Tc-99m pertechnetate (TcO4-) is in the +7 oxidation state. Pertechnetate is chemically similar to iodide and is actively trapped by the thyroid gland, salivary glands, gastric mucosa, and choroid plexus, making it directly useful for thyroid imaging, Meckel diverticulum scans, and salivary gland imaging without any further chemical processing. For kit-based preparations, however, pertechnetate must be reduced to a lower oxidation state so that it can bind to the kit ligand. Stannous chloride (SnCl2) is the standard reducing agent in virtually all Tc-99m kits, reducing technetium from the +7 state to typically +4 or +5, after which the reduced technetium chelates with the kit ligand.

Common Tc-99m Radiopharmaceuticals and Their Chemistry

The range of Tc-99m radiopharmaceuticals spans many clinical applications. Tc-99m MDP (medronate) is a phosphonate complex in the +4 oxidation state used for bone imaging. Tc-99m sestamibi is a lipophilic cation in the +1 state (isonitrile complex) used for cardiac perfusion and parathyroid imaging. Tc-99m tetrofosmin is a diphosphine complex in the +5 state, also used for cardiac perfusion. Tc-99m MAA consists of macroaggregated albumin particles labeled with Tc-99m for lung perfusion imaging. Tc-99m sulfur colloid is a colloidal preparation used for liver/spleen imaging, GI bleeding studies, and lymphoscintigraphy. Tc-99m DTPA is a chelate complex used as a GFR agent for renal imaging and as an aerosol for lung ventilation studies. Tc-99m MAG3 is a tubular secretion agent for renal imaging. Tc-99m HMPAO (exametazime) and Tc-99m ECD (bicisate) are lipophilic complexes used for brain perfusion imaging, with HMPAO also used for white blood cell labeling. Tc-99m mebrofenin is an IDA derivative for hepatobiliary imaging. Tc-99m-labeled red blood cells are used for GI bleeding studies and MUGA scans. Tc-99m DMSA is a cortical renal agent in the +3 state.

Kit Preparation

General Procedure

Kit preparation follows a standardized sequence. First, Tc-99m pertechnetate is eluted from the generator. Generator QC is performed, including Mo-99 and aluminum breakthrough testing. Next, the pertechnetate is aseptically added to the lyophilized kit vial, which contains the ligand, the reducing agent (stannous chloride), and any necessary stabilizers and buffers. An incubation period follows -- some kits label immediately, while others require 15 to 30 minutes or heating. After incubation, radiochemical purity testing is performed. Finally, all relevant information is recorded, including lot numbers, activity, time, and expiration.

Factors Affecting Labeling Efficiency

Several factors can compromise labeling efficiency. The activity and volume of pertechnetate added must fall within the kit's recommended ranges; too much activity can exceed the reducing capacity of the stannous chloride. Air (oxygen) in the vial oxidizes Sn2+ to Sn4+, depleting the available reducing agent -- some kits require nitrogen purging to maintain anaerobic conditions. The age of the eluate matters: pertechnetate from the first elution of the day is preferred because later elutions may contain more impurities. Other oxidizing agents, such as excess aluminum or contamination from expired kits, can interfere. Temperature requirements vary: some kits require boiling (MAA, sulfur colloid) while others need only room temperature incubation. Finally, pH must be within the specified range for optimal complexation.

Radiochemical Purity Testing by TLC

Thin-layer chromatography (TLC) separates radiochemical species based on their differential migration along a stationary phase. Two TLC systems are typically needed to identify three possible species: free pertechnetate (unbound TcO4-), hydrolyzed-reduced Tc-99m (colloidal TcO2), and the bound Tc-99m complex (the desired product). In System 1, using ITLC-SG with acetone or MEK as the solvent, free pertechnetate migrates to the solvent front (Rf approximately 1.0) while the bound complex and colloid remain at the origin. In System 2, using ITLC-SG with saline, both free pertechnetate and the bound complex migrate to the solvent front while colloid remains at the origin. The percentage of bound complex is calculated as 100% minus the percentage of free pertechnetate minus the percentage of colloid, and must meet a minimum RCP of 90 to 95% depending on the specific radiopharmaceutical.

Special Preparations

Tc-99m Labeled Red Blood Cells

Three methods exist for labeling red blood cells with Tc-99m, each with different labeling efficiency and complexity. The in vitro method (UltraTag kit) offers the highest labeling efficiency at greater than 97%. Blood is withdrawn, stannous pyrophosphate is added to pre-tin the RBCs, and then Tc-99m pertechnetate is added. The pertechnetate enters the RBCs, is reduced by intracellular Sn2+, and binds to the beta chain of hemoglobin. The modified in vivo method involves injecting stannous pyrophosphate intravenously, waiting 20 minutes, withdrawing blood, adding pertechnetate in vitro, and then reinjecting the labeled blood. The in vivo method is simplest but has the lowest labeling efficiency at approximately 75 to 80%: stannous pyrophosphate is injected IV, followed 20 minutes later by IV injection of pertechnetate. Several drugs can reduce RBC labeling efficiency, including heparin, doxorubicin, and iodinated contrast agents.

Tc-99m MAA Preparation

The MAA kit contains pre-formed human albumin aggregated particles. Pertechnetate is added and gently mixed -- vigorous shaking must be avoided because it breaks the particles, reducing their size and compromising the study. Each vial contains 200,000 to 700,000 particles, and a typical adult dose includes 200,000 to 500,000 particles for lung perfusion imaging. The particle count must be reduced in certain clinical situations, including pediatric patients, right-to-left cardiac shunts, severe pulmonary hypertension, and post-pneumonectomy, to avoid hemodynamic compromise from microembolization of systemic capillary beds.

<image>A detailed diagram of the Mo-99/Tc-99m generator system showing the alumina column with Mo-99 (as molybdate) adsorbed, the saline eluent being drawn through, and Tc-99m pertechnetate being eluted into a collection vial. Include a graph showing the transient equilibrium curve with Mo-99 decay and Tc-99m ingrowth/equilibrium over time, marking the optimal elution time at approximately 23 hours. Label the key components: lead shielding, alumina column, saline inlet, eluate outlet, air filter.</image>

<image>A step-by-step illustration of Tc-99m kit preparation quality control. Show the workflow: (1) generator elution, (2) Mo-99 breakthrough test using a lead pig and dose calibrator, (3) Al breakthrough colorimetric spot test with comparison to standard, (4) kit reconstitution with pertechnetate addition, (5) TLC setup with ITLC-SG strips and two solvent systems (acetone and saline), (6) cutting and counting TLC strips to determine percentages of free pertechnetate, colloid, and bound complex. Include the acceptance criteria at each step.</image>

<image>A comparison of the three methods of Tc-99m red blood cell labeling: in vitro (UltraTag), modified in vivo, and in vivo. For each method, show the sequence of steps with timing, the labeling efficiency achieved, and the pros and cons. Illustrate the mechanism of labeling: stannous ion enters RBC, reduces incoming pertechnetate, which then binds to the beta chain of hemoglobin inside the cell.</image>

Clinical Pearls

The Mo-99/Tc-99m generator is the backbone of diagnostic nuclear medicine. Understanding transient equilibrium is fundamental to efficient generator use and daily scheduling -- maximum Tc-99m yield is available approximately 23 hours after the last elution.

Mo-99 breakthrough testing must be performed before using the first elution of a new generator. Mo-99 is a beta emitter with a 66-hour half-life that delivers unnecessary and prolonged radiation dose to patients if administered.

If a bone scan shows unexpected thyroid, stomach, or salivary gland uptake, the most likely explanation is free pertechnetate from poor radiochemical purity. The TLC results from kit preparation should be reviewed to confirm.

Oxygen is the enemy of kit preparation. It oxidizes stannous chloride, depleting the reducing agent and impairing labeling efficiency. Air should never be injected into kits that require anaerobic conditions.

In vitro RBC labeling provides the highest labeling efficiency and is the preferred method for GI bleeding studies, where free pertechnetate in the GI tract would cause false-positive results that could prompt unnecessary intervention.

MAA particle count must be reduced in patients with right-to-left cardiac shunts, severe pulmonary hypertension, or post-pneumonectomy to avoid hemodynamic compromise from microembolization of systemic capillary beds.

The Tc-99m generator can be eluted multiple times daily, but each successive elution within the same day yields less activity because insufficient time has elapsed for Tc-99m to accumulate.

References

• Saha GB. Fundamentals of Nuclear Pharmacy. 7th ed. Springer; 2018. Chapters 5-7.
• Zolle I, ed. Technetium-99m Pharmaceuticals: Preparation and Quality Control in Nuclear Medicine. Springer; 2007.
• Schwarz SW, et al. Tc-99m generator and kit preparation quality control. J Nucl Med Technol. 2022;50(2):89-98.
• National Academies of Sciences. Molybdenum-99 for Medical Imaging. National Academies Press; 2016.

Read this lecture as Markdown